Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:28:58.000Z thumbnail image
  5. Check
    4 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, representing an update in the study's primary and secondary outcome assessment timeline from 12 weeks to 168 weeks for patients with squamous cell carcinoma of the head and neck receiving pembrolizumab for residual disease after radiation therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:15.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    53%
    Check dated 2024-05-22T21:08:15.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:23:43.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.